AGENTS AND METHODS FOR INHIBITING MIR-148A FOR THE MODULATION OF CHOLESTEROL LEVELS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 30, 2016
app pub date -
Jul 23, 2014
filing date -
Jul 24, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Elevated blood levels of low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) are strongly linked to circulatory disorders, e.g. cardiovascular disease such as atherosclerosis, angina, coronary heart disease, heart attack, stroke, etc. The LDL receptor (LDLR) mediates uptake of LDL-C (low density lipoprotein-cholesterol) by, e.g. hepatic cells. As described herein, miR-148a regulates LDLR expression in human hepatic cells. Accordingly, described herein are methods and compositions relating to, e.g. regulating cholesterol levels by modulating the level of miR-148a.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully